Every Form 4 that Cabaletta Bio, Inc. (CABA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CABA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CABA filings page.
Cabaletta Bio director Shawn Tomasello received a grant of stock options covering 22,000 shares of Common Stock. The options have an exercise price of $3.22 per share and are held directly. This is a compensation-related award rather than an open-market purchase or sale.
The option vests in full on the earlier of June 9, 2027 or the date of Cabaletta Bio’s next annual meeting of stockholders, and expires on June 8, 2036. Following this grant, Tomasello holds 22,000 option-derived shares related to this award.
Cabaletta Bio director Simon Mark received a grant of stock options as part of his compensation. The award covers 22,000 options to buy Cabaletta Bio common stock at an exercise price of $3.22 per share, expiring on June 8, 2036.
The options will vest in full on the earlier of June 9, 2027 or the date of the company’s next annual stockholder meeting. This is a compensation-related grant, not an open-market purchase or sale of shares.
Cabaletta Bio, Inc. director Richard C. Henriques Jr. received a grant of stock options covering 22,000 shares of common stock. The options have an exercise price of $3.22 per share and expire on June 8, 2036. They will vest in full on the earlier of June 9, 2027 or the date of the company’s next annual stockholder meeting.
Cabaletta Bio director Catherine Bollard received a stock option grant covering 22,000 shares of common stock. The option has an exercise price of $3.22 per share and gives her the right to buy 22,000 shares in the future. It vests in full on the earlier of June 9, 2027 or the date of the company’s next annual stockholder meeting, providing equity-based compensation rather than an open-market share purchase.
Cabaletta Bio director Scott C. Brun received a grant of stock options covering 22,000 shares of common stock. The options have an exercise price of $3.22 per share and expire on June 8, 2036. They vest in full on the earlier of June 9, 2027 or the date of the company’s next annual stockholder meeting. Following this award, Brun holds stock options for 22,000 shares. This is a compensation-related grant, not an open-market purchase or sale of shares.
Cabaletta Bio, Inc. reported that Chief Business Officer Arun Das received a grant of stock options. The award covers 175,000 options to buy Cabaletta Bio common stock at an exercise price of $0.00 per share, representing a compensatory equity grant rather than a market purchase.
According to the vesting terms, 25% of the shares underlying this option vest and become exercisable on March 1, 2027. The remaining options vest in twelve substantially equal quarterly installments after that date, as long as he continues in service through each vesting date.
Cabaletta Bio, Inc. reported that its General Counsel, Gerard Michael, received a grant of stock options covering 175,000 shares of common stock. The options were awarded at an exercise price of $0.00 per share, reflecting a compensatory equity award rather than an open-market purchase.
According to the vesting terms, 25% of the shares subject to the option will vest and become exercisable on March 1, 2027. The remaining 75% will vest in twelve substantially equal quarterly installments after that date, conditioned on his continued service with the company on each vesting date.
Cabaletta Bio, Inc. reported that President, Science & Tech. Gwendolyn Binder acquired a grant of 225,000 stock options on March 2, 2026. These options have a stated price of $0.00 per share and represent rights to buy Cabaletta Bio common stock in the future.
According to the vesting terms, 25% of the shares underlying this option vest and become exercisable on March 1, 2027, with the remaining options vesting in twelve substantially equal quarterly installments thereafter, contingent on her continued service on each vesting date.
Cabaletta Bio, Inc. reported that Chief Medical Officer David J. Chang acquired a new stock option award covering 225,000 shares of company stock. This option was granted as a derivative security and represents his total option holdings after the reported transaction.
According to the vesting terms, 25% of the shares underlying this option will vest and become exercisable on March 1, 2027. The remaining shares will vest in twelve substantially equal quarterly installments after that date, conditioned on his continued service with the company on each vesting date.
Nichtberger Steven reported acquisition or exercise transactions in this Form 4 filing.
Cabaletta Bio reported that President and CEO Steven Nichtberger received a grant of stock options covering 674,000 shares of the company’s common stock. The options were awarded at no cost to him, increasing his directly held option position to 674,000 options after the grant.
According to the vesting terms, 25% of the shares underlying this option will vest and become exercisable on March 1, 2027. The remaining 75% will vest in twelve substantially equal quarterly installments after that date, conditioned on his continued service with the company on each vesting date.
Cabaletta Bio, Inc. reported that its Chief Financial Officer, Anup Marda, received a grant of stock options covering 225,000 shares of common stock. The options were acquired as a grant, with 25% scheduled to vest and become exercisable on March 1, 2027, and the remaining 75% vesting in twelve substantially equal quarterly installments thereafter, conditioned on his continued service with the company on each vesting date.
Cabaletta Bio Chief Medical Officer David J. Chang reported buying 8,800 shares of Cabaletta Bio common stock on January 21, 2026. The purchase was made in an open-market transaction coded “P” at a price of $2.26 per share. After this transaction, he directly owns 8,800 common shares of the company.
Cabaletta Bio, Inc. officer Gwendolyn Binder, President, Science & Tech., reported an open-market purchase of company stock. On January 21, 2026, she bought 11,312 shares of Cabaletta Bio common stock at a price of $2.1891 per share.
Following this transaction, Binder directly holds a total of 31,312 shares of Cabaletta Bio common stock, according to the filing.
Cabaletta Bio director reports indirect stock purchase
A reporting person associated with Cabaletta Bio, Inc. bought 22,725 shares of the company’s common stock on January 21, 2026 at a price of $2.2144 per share. Following this transaction, the reporting person is shown as beneficially owning 22,725 common shares, all held indirectly.
The shares are held through an entity named Shawn Tomasello Consulting LLC, rather than in the individual’s direct name. The filing is signed by an attorney-in-fact, indicating the use of an authorized representative to submit the Form 4.
Cabaletta Bio, Inc. insider trade: Chief Commercial Officer Steve Gavel reported purchasing 22,170 shares of Cabaletta Bio common stock on January 21, 2026. The Form 4 shows this as an open-market buy coded "P" at a weighted average price of $2.265 per share.
According to the filing, the shares were acquired in multiple trades at prices ranging from $2.26 to $2.27 per share, and Gavel beneficially owns 22,170 common shares following this transaction, held directly. The insider also notes a commitment to make detailed trade price information available to the company, its security holders, or the SEC staff upon request.
Cabaletta Bio, Inc. director Catherine Bollard reported a purchase of 4,405 shares of the company’s common stock. The transaction took place on 01/21/2026 at a price of $2.2661 per share, according to a Form 4 insider trading report.
Following this open-market purchase, Bollard’s reported beneficial ownership increased to 5,405 shares, held directly. The filing indicates the transaction code "P," which denotes a purchase of non-derivative securities.
Cabaletta Bio, Inc. President & CEO Steven Nichtberger reported buying 45,000 shares of the company’s common stock on January 21, 2026 at a weighted average price of $2.2395 per share. The filing notes these shares were purchased in multiple trades at prices ranging from $2.1985 to $2.26. Following this direct purchase, he beneficially owned 1,031,483 shares held directly.
The Form 4 also shows an additional 363,000 shares reported as indirectly held by the 2017 Nichtberger Family Trust, for which he disclaims beneficial ownership. The price detail and range are available on request from the issuer or the SEC staff, as stated in the footnote.
Cabaletta Bio director Simon Mark reported buying additional company stock. On January 21, 2026, he purchased 11,061 shares of Cabaletta Bio common stock at a weighted average price of $2.2838 per share. The filing notes that these shares were bought in multiple trades at prices ranging from $2.245 to $2.32 and that detailed trade information is available upon request.
After this transaction, Mark beneficially owned 147,205 shares of Cabaletta Bio common stock directly. The filing also reports 7,000 shares held indirectly by his spouse, reflecting additional beneficial ownership connected to him.
Cabaletta Bio, Inc. General Counsel Gerard Michael reported a purchase of 6,600 shares of common stock. The Form 4 shows that on 01/21/2026, he bought 6,600 Cabaletta Bio common shares at a weighted average price of $2.2696 per share, coded as a purchase (P). After this transaction, he beneficially owned 6,600 common shares held directly.
The filing notes that the reported price is a weighted average, with individual purchase prices ranging from $2.269 to $2.2699 per share, and that detailed price breakdowns are available from the company or the reporting person upon request.
Cabaletta Bio (CABA) disclosed a Form 4 showing its Chief Commercial Officer received a grant of stock options to purchase 275,000 shares at an exercise price of $2.49 on October 13, 2025.
The option was granted under the company’s 2025 Inducement Plan pursuant to NASDAQ Listing Rule 5635(c)(4). It vests with 25% on October 13, 2026, and the remainder in twelve substantially equal quarterly installments thereafter, subject to continued service. The option expires on October 12, 2035. Following the grant, the reporting person holds 275,000 derivative securities directly.